The enzalutamide/leuprolide combo also led to statistically significant improvements in time to PSA progression and time to start of new antineoplastic therapy.

Findings suggest many patients with localized disease can delay surgery or radiation without increasing their mortality risk.

“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.

“What is precision medicine? This is not just a vague term; it really looks at individual characteristics of a patient to decide treatment," said Leonard G. Gomella, MD, FACS.

“The more we can use AI to streamline all the less attractive aspects of our job, the better,” says David Canes, MD.

The PSMA-PET imaging product is now approved for the selection of patients with metastatic prostate cancer for whom 177Lu-PSMA-617 is indicated.

If automation can enhance efficiency and reduce provider dissatisfaction while improving patient health, there’s a strong case for introducing automation into the mix, writes industry expert Eric Demers.

"The government is spending more in Medicare, we are getting more people with prostate cancer, more deaths with prostate cancer, [and] more metastasis with prostate cancer. While it is so simple: today, PSA is still there," says Navin Shah, MD, MS, FACS, FICS, FACIP.

The investigators used data from the National Inpatient Sample database to identify 5280 patients with non-metastatic bladder cancer who underwent RC from 2016 to 2019.

"While past global studies have supported the use of Xtandi plus ADT in men with mHSPC, it is encouraging to see these results replicated for patients in mainland China," said Zhou Fangjian, MD.

"We think this is an important call to action for the NCCN to follow in the footsteps of the AUA, who recently removed VLR from its prostate cancer guidelines in its most recent update," says Kevin Shee, MD, PhD.

“There is an urgent need for new treatment options for [patients with] urothelial carcinoma, many of whom find themselves out of options after progressing on immune checkpoint inhibitors," said Sergio Santillana, MD.

Urologists should watch early adopters of MVPs to know what to expect.

"Our recommendation is to adopt a Mediterranean diet enlisting the help of a dietician, because people absorb nutrients in different ways, depending on the food, the digestive system, the person’s genotype and possibly their microbiome," says Permal Deo, MD.

Avelumab is approved by the FDA as a maintenance therapy for patients with locally advanced/metastatic urothelial carcinoma that has not progressed with first-line, platinum-based chemotherapy.

"Our hope is that this study, and others, will encourage a review of the levels of nitrate that are allowed in water, in order to ensure that there is no risk to human health,” said Carolina Donat-Vargas, PhD, MPH.

"This year's Summit was one of the biggest and most exciting so far," says Kevin Koo, MD, MPH.

Once patients had a PSA level of 0.25 ng/mL or higher, the risk of mortality increased by approximately 50%.

“[The ability of] remote patient monitoring to provide targeted clinical information to physicians and elevate critical information for review and earlier intervention is enhancing patient communication and care delivery,” said Jim Brown, MD.

“As a whole, the benefits of the lenvatinib plus pembrolizumab combination proved to be durable, statistically significant, and clinically meaningful,” said senior author Camillo Porta, MD.

The investigators retrospectively analyzed ABU case log data on 8 different BPH surgical procedures ranging from 2008 to 2021.

"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.

"Increasing regulation, excess bureaucracy, decreasing autonomy, declining reimbursement, and increased administrative burdens are all increasing the risk of burnout," says Andrew M. Harris, MD.

"The pendulum is swinging back. It’s all about provider education, hammering home the point that we have to do appropriate screening," says urologist Ryan Hankins, MD.

"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.